Skip to main content

Chronic Rhinosinusitis With Nasal Polyposis

3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Keymed Biosciences
Keymed BiosciencesChina - Chengdu
3 programs
2
1
CM310Phase 31 trial
CM512Phase 21 trial
CM512Phase 21 trial
Active Trials
NCT06930612Not Yet Recruiting120Est. Sep 2026
NCT07519577Not Yet Recruiting120Est. May 2028
NCT05436275Completed180Est. Jun 2024
Regeneron
RegeneronTARRYTOWN, NY
1 program
DupilumabN/AMonoclonal Antibody
Sanofi
SanofiPARIS, France
1 program
DupilumabN/AMonoclonal Antibody1 trial
Active Trials
NCT06393946Active Not Recruiting150Est. Jul 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
Keymed BiosciencesCM310
Keymed BiosciencesCM512
Keymed BiosciencesCM512
SanofiDupilumab

Clinical Trials (4)

Total enrollment: 570 patients across 4 trials

NCT05436275Keymed BiosciencesCM310

A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）

Start: Aug 2022Est. completion: Jun 2024180 patients
Phase 3Completed
NCT07519577Keymed BiosciencesCM512

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）

Start: May 2026Est. completion: May 2028120 patients
Phase 2Not Yet Recruiting
NCT06930612Keymed BiosciencesCM512

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）

Start: May 2025Est. completion: Sep 2026120 patients
Phase 2Not Yet Recruiting
NCT06393946SanofiDupilumab

Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France

Start: Oct 2023Est. completion: Jul 2026150 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.